Table 1 Study characteristics for all subjects
From: Neuroanatomical regions associated with non-progressive dysarthria post-stroke: a systematic review
Study | Country | Sample size (n = 1150) | Enrollment periodb years;months | Mean age (range) | Gender males n | Stroke type | Neuroimaging technique used | Days to initial imaging | Method of dysarthria assessmentj | Days to dysarthria assessmentj |
|---|---|---|---|---|---|---|---|---|---|---|
Ackermann et al. [17] | Germany | 12 | NSc | 55.8 (34–75) | 8 | Ischemic | MRIe and/or CTf |  ≤ 7 | Neurophonetic test battery |  ≤ 7 |
Barth et al. [35] | Switzerland | 34 | 3;0 | 67 (24–87) | 25 | Ischemic | MRI | 3–7 | Clinical | NS |
Bassetti et al. [36] | Switzerland | 36 | 3;0 | 64 (20–80) | 26 | Ischemic | MRI and CT |  ≤ 7 | Clinical | NS |
Beckmann et al. [37] | Turkey | 64 | 4;0 | 64.2 (29–87) | 30 | Ischemic | MRI and CT |  ≤ 5 | Clinical | NS |
Canbaz et al. [16] | Turkey | 55 | 0;3 | 65.5 (18–97) | 36 | Ischemic | MRI and/or CT | NS | Clinical |  ≤ 3 |
Chung et al. [39] | Korea | 215 | 3;0 | 57.4 (27–90) | 133 | Hemorrhagic | CT | NS | Clinical | NS |
Erdemoglu and Duman [38] | Turkey | 21 | NS | 62 (31–85) | 14 | Ischemic | CT |  ≤ 3 | Clinical | NS |
Kase et al. [41] | United States of America | 66 | 5;0 | 61(18–88) | 46 | Ischemic | MRI or CT | NS | Clinical | NS |
Kataoka et al. [42] | Japan | 49 | 11;0 | 67.2 ± 6.7d | 31 | Ischemic | MRI | 7–14 | Clinical | 3–7 |
Kim et al. [49] | South Korea | 26 | 8;0 | 58.6 (34–89) | 14 | Hemorrhagic | MRI or CT |  ≤ 21 | Clinical | On admission |
Kim [46] | South Korea | 13 | 5;0 | 56 (33–72) | 9 | Ischemic | MRI and/or CT |  ≤ 5 g | Clinical | NS |
Kim [47] | South Korea | 130 | 8;0 | 57 (28–84) | 90 | Ischemic | MRI | NS | Clinical | NS |
Kim and Kim [40] | South Korea, Canada | 40 | 6;9 | 65 (47–81) | 23 | Ischemic | MRI |  ≤ 10 | Clinical | NS |
Kim et al. [18] | South Korea | 37 | 3;4 | 61 (36–85) | 19 | Ischemic | MRI and/or CT | NS | Clinical | NS |
Min et al. [48] | South Korea | 31 | 1;3 | 59 (42–80) | 24 | Ischemic | MRI | NS | Clinical | NS |
Okuda et al. [43] | Japan | 12 | 9;0 | 67.8 (49–81) | 10 | Ischemic | MRI | 10–54 | Clinical | NS |
Schmahmann et al. [50] | US | 25 | 8;0 | 61 (32–82) | 15 | Ischemic | MRI or CT | NS | Clinical | NS |
Tanaka et al. [44] | Japan | 31 | 3;0 | 68.1 ± 11.6 | 19 | Ischemic | MRI |  < 1 h | Clinical | On admission |
Tohgi et al. [45] | Japan | 64 | NS | 61.9 (NS) | 47 | Ischemic | MRI and CT | CT: on admission MRI: ≤ 30 | Clinical | NS |
Urban et al. [31] | Germany | 68 | 5;0 | 65.2 (34–86) | 43 | Ischemic | MRI or CT |  ≤ 3 | Neurophonetic test battery |  ≤ 3 |
Urban et al. [32] | Germany | 18 | NS | 64 (45–82) | 13 | Ischemic | MRI and/or CT | NS | Neurophonetic test battery |  ≤ 5 |
Urban et al. [33] | Germany | 18 | NS | NS | NS | Ischemic | MRI and/or CT |  ≤ 1 | Neurophonetic test battery |  ≤ 7 |
Urban et al. [34] | Germany | 62 | 3;2 | 64.7 (34–87) | 44 | Ischemic | MRI and/or CT | NS | Neurophonetic test battery |  ≤ 3 |
Vuilleumier et al. [19] | Switzerland | 23a | 3;1 | 62.5 (30–85) | 18 | Ischemic | MRI |  ≤ 16i | Clinical | 1–16 |